Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib in TSC1 or TSC2 Mutated Tumors (MATCH Subprotocol M)
NCT06390865Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2017
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sapanisertib in malignant solid neoplasm, lymphoma and multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 3 years. Started Mar 2017; status: active, not recruiting.
02
Drugs
sapanisertib
03
Conditions
malignant solid neoplasmlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06390865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390865.